No Data
No Data
Jiangsu Apon Medical Technology (300753.SZ): Some directors and senior management personnel have cumulatively increased their shareholding by 0.6636%.
Jiangsu Apon Medical Technology (300753.SZ) announced on August 6th that as of the disclosure date of this announcement, the shareholding plan has expired and been fully implemented. Some directors and senior executives of the company have increased their holdings by 0.7984 million shares, accounting for 0.6636% of the total share capital of the company, with a total investment of 7.725 million yuan.
Jiangsu Apon Medical Technology (300753.SZ): In the field of electroencephalogram technology, the company is one of the few domestic enterprises that master the technology of monitoring the depth of anesthesia index.
Jiangsu Apon Medical Technology (300753.SZ) stated on the investor platform that it is a national specialized, special and new small giant enterprise. In the field of pain management, the company is one of the earliest domestic companies to master a series of core technologies, including high-precision drug infusion technology, all-round safety monitoring technology, pain management information platform technology, and the only corporate unit to participate in the formulation of the industry standard for portable electric infusion pumps. In the field of nasal and upper airway management, the company is one of the earliest domestic companies to enter the nasal irrigation track, taking the lead in innovatively proposing a new concept of sequential treatment for nasal cleaning and innovatively developing treatments for different rhinitis conditions.
Jiangsu Apon Medical Technology (300753.SZ): The company's R&D investment in 2023 accounts for 8.66% of its revenue.
On July 19th, Gelunhui reported that Jiangsu Apon Medical Technology (stock code: 300753.SZ) has been committed to research and development technology investment and planning since its listing, and has continuously optimized its research and development organizational structure. The company's R&D investment accounted for 8.66% of its revenue in 2023, and it has built a vertical product management system centered around its core main business, and a research and development organizational structure system supported by a product management platform and special technology. It will gradually sort out the existing products under research, focus on core technology areas, strengthen strategic cooperation with external industries, universities, and research institutes, and enhance product development efficiency through strict product project management. Through its main business.
AH trends diverge, Hang Seng Index up 0.6%, CNOOC up 4%, national bond futures slightly rebound.
Rare earth permanent magnets concept stocks pull back, photovoltaic and lithography themes also weaken. Hong Kong's real estate, banks, and oil & gas stocks are strong, CNOOC up 4%, Agricultural Bank of China and China Merchants Bank rise more than 2%. After experiencing a sharp drop yesterday, national bond futures rebounded in early trading, with 10-year and 30-year national bond futures contracts rising nearly 0.1% in early trading.
Jiangsu Apon Medical Technology (SZ300753): The company's NOCCI series of products were not included in the joint procurement, and the participating products in the alliance procurement were pain management analgesic pump products.
On June 11th, Gelunhui reported that Jiangsu Apon Medical Technology (300753.SZ) stated on the investor interactive platform that the company's Norclean series products were not part of the joint procurement, and the products participating in the alliance procurement were pain management analgesic pump products. Regarding the nasal washer brand mentioned by you, it is one of the nasal cavity flushing track brands, and the company has not yet understood the specific situation. The company's Norclean nasal cavity care spray products are also deployed in both clinical and retail channels, covering platforms such as hospitals, offline retail pharmacies, and online internet plus-related, and have won the double champion of nasal washer sales volume for 8 consecutive years on Tmall and jd.com, and won the Tmall Annual Category User Education Pioneer Award and the JD Medical Device
Aipon Healthcare (300753.SZ) 2023 annual equity distribution: 0.65 yuan for every 10 shares, share registration on May 31
Aipon Healthcare (300753.SZ) issued an announcement. The company's 2023 equity distribution plan is: Based on the company's total...
No Data